PritorPlus

Country: European Union

Language: English

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

Telmisartan, hydrochlorothiazide

Available from:

Bayer AG

ATC code:

C09DA07

INN (International Name):

telmisartan, hydrochlorothiazide

Therapeutic group:

Agents acting on the renin-angiotensin system

Therapeutic area:

Hypertension

Therapeutic indications:

Treatment of essential hypertension.PritorPlus fixed-dose combination (40 mg telmisartan / 12.5 mg hydrochlorothiazide, 80mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on telmisartan alone.PritorPlus fixed-dose combination (80 mg telmisartan / 25 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on PritorPlus (80 mg telmisartan / 12.5 mg hydrochlorothiazide) or patients who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.

Product summary:

Revision: 37

Authorization status:

Authorised

Authorization date:

2002-04-22

Patient Information leaflet

                                59
B. PACKAGE LEAFLET
60
PACKAGE LEAFLET: INFORMATION FOR THE USER
PRITORPLUS 40 MG/12.5 MG TABLETS
telmisartan/hydrochlorothiazide
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What PritorPlus is and what it is used for
2.
What you need to know before you take PritorPlus
3.
How to take PritorPlus
4.
Possible side effects
5.
How to store PritorPlus
6.
Contents of the pack and other information
1.
WHAT PRITORPLUS IS AND WHAT IT IS USED FOR
PritorPlus is a combination of two active substances, telmisartan and
hydrochlorothiazide in one
tablet. Both of these substances help to control high blood pressure.
-
Telmisartan belongs to a group of medicines called angiotensin II
receptor antagonists.
Angiotensin-II is a substance produced in your body which causes your
blood vessels to narrow
thus increasing your blood pressure. Telmisartan blocks the effect of
angiotensin II so that the
blood vessels relax, and your blood pressure is lowered.
-
Hydrochlorothiazide belongs to a group of medicines called thiazide
diuretics, which cause your
urine output to increase, leading to a lowering of your blood
pressure.
High blood pressure, if not treated, can damage blood vessels in
several organs, which could lead
sometimes to heart attack, heart or kidney failure, stroke, or
blindness. There are usually no symptoms
of high blood pressure before damage occurs. Thus it is important to
regularly measure blood pressure
to verify if it is within the normal range.
PritorPlus is used to treat high blood pressure (essential
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
PritorPlus 40 mg/12.5 mg tablets
PritorPlus 80 mg/12.5 mg tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
PritorPlus 40 mg/12.5 mg tablets
Each tablet contains 40 mg telmisartan and 12.5 mg
hydrochlorothiazide.
PritorPlus 80 mg/12.5 mg tablets
Each tablet contains 80 mg telmisartan and 12.5 mg
hydrochlorothiazide.
Excipients with known effect
PritorPlus 40 mg/12.5 mg tablets
Each tablet contains 112 mg of lactose monohydrate equivalent to 107
mg lactose anhydrous.
Each tablet contains 169 mg sorbitol (E420).
PritorPlus 80 mg/12.5 mg tablets
Each tablet contains 112 mg of lactose monohydrate equivalent to 107
mg lactose anhydrous.
Each tablet contains 338 mg sorbitol (E420).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablet.
PritorPlus 40 mg/12.5 mg tablets
Red and white oblong shaped two layer tablet of 5.2 mm engraved with
the code number 'H4'.
PritorPlus 80 mg/12.5 mg tablets
Red and white oblong shaped two layer tablet of 6.2 mm engraved with
the code number 'H8'.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Treatment of essential hypertension.
PritorPlus fixed dose combination (40 mg telmisartan/12.5 mg
hydrochlorothiazide (HCTZ) and
80 mg telmisartan/12.5 mg HCTZ) is indicated in adults whose blood
pressure is not adequately
controlled on telmisartan alone.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The fixed dose combination should be taken in patients whose blood
pressure is not adequately
controlled by telmisartan alone. Individual dose titration with each
of the two components is
recommended before changing to the fixed dose combination. When
clinically appropriate, direct
change from monotherapy to the fixed combination may be considered.
3
•
PritorPlus 40 mg/12.5 mg may be administered once daily in patients
whose blood pressure is
not adequately controlled by Pritor 40 mg
•
PritorPlus 80 mg/12.5 mg may be administered once daily in patients
whose blood pressure is
not ad
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 14-09-2022
Summary of Product characteristics Summary of Product characteristics Bulgarian 14-09-2022
Public Assessment Report Public Assessment Report Bulgarian 12-11-2015
Patient Information leaflet Patient Information leaflet Spanish 14-09-2022
Public Assessment Report Public Assessment Report Spanish 12-11-2015
Patient Information leaflet Patient Information leaflet Czech 14-09-2022
Public Assessment Report Public Assessment Report Czech 12-11-2015
Patient Information leaflet Patient Information leaflet Danish 14-09-2022
Public Assessment Report Public Assessment Report Danish 12-11-2015
Patient Information leaflet Patient Information leaflet German 14-09-2022
Public Assessment Report Public Assessment Report German 12-11-2015
Patient Information leaflet Patient Information leaflet Estonian 14-09-2022
Public Assessment Report Public Assessment Report Estonian 12-11-2015
Patient Information leaflet Patient Information leaflet Greek 14-09-2022
Public Assessment Report Public Assessment Report Greek 12-11-2015
Patient Information leaflet Patient Information leaflet French 14-09-2022
Public Assessment Report Public Assessment Report French 12-11-2015
Patient Information leaflet Patient Information leaflet Italian 14-09-2022
Public Assessment Report Public Assessment Report Italian 12-11-2015
Patient Information leaflet Patient Information leaflet Latvian 14-09-2022
Public Assessment Report Public Assessment Report Latvian 12-11-2015
Patient Information leaflet Patient Information leaflet Lithuanian 14-09-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 14-09-2022
Public Assessment Report Public Assessment Report Lithuanian 12-11-2015
Patient Information leaflet Patient Information leaflet Hungarian 14-09-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 14-09-2022
Public Assessment Report Public Assessment Report Hungarian 12-11-2015
Patient Information leaflet Patient Information leaflet Maltese 14-09-2022
Public Assessment Report Public Assessment Report Maltese 12-11-2015
Patient Information leaflet Patient Information leaflet Dutch 14-09-2022
Public Assessment Report Public Assessment Report Dutch 12-11-2015
Patient Information leaflet Patient Information leaflet Polish 14-09-2022
Public Assessment Report Public Assessment Report Polish 12-11-2015
Patient Information leaflet Patient Information leaflet Portuguese 14-09-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 14-09-2022
Public Assessment Report Public Assessment Report Portuguese 12-11-2015
Patient Information leaflet Patient Information leaflet Romanian 14-09-2022
Public Assessment Report Public Assessment Report Romanian 12-11-2015
Patient Information leaflet Patient Information leaflet Slovak 14-09-2022
Public Assessment Report Public Assessment Report Slovak 12-11-2015
Patient Information leaflet Patient Information leaflet Slovenian 14-09-2022
Summary of Product characteristics Summary of Product characteristics Slovenian 14-09-2022
Public Assessment Report Public Assessment Report Slovenian 12-11-2015
Patient Information leaflet Patient Information leaflet Finnish 14-09-2022
Public Assessment Report Public Assessment Report Finnish 12-11-2015
Patient Information leaflet Patient Information leaflet Swedish 14-09-2022
Public Assessment Report Public Assessment Report Swedish 12-11-2015
Patient Information leaflet Patient Information leaflet Norwegian 14-09-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 14-09-2022
Patient Information leaflet Patient Information leaflet Icelandic 14-09-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 14-09-2022
Patient Information leaflet Patient Information leaflet Croatian 14-09-2022
Public Assessment Report Public Assessment Report Croatian 12-11-2015

Search alerts related to this product

View documents history